Combination Chemotherapy with 5-Fluorouracil and Heptaplatin as First-line Treatment in Patients with Advanced Gastric Cancer

• Published in: Journal of Korean medical science pp. 369 - 373
• Main Authors: Min Young Joo, Bang Sung Jo, Shin Jung Woo, Kim Do Ha, Park Jae Hoo, Kim Gyu Yeol, Ko Byung Kyun, Choi Dae Hwa, Cho Hong Rae
• Format: Journal Article
• Language: Korean
• Published: 대한의학회 01-06-2004
• Subjects: 의학일반
• ISSN: 1011-8934; 1598-6357

Heptaplatin is a recently developed platinum derivative. This agent has been report-ed
to have a response rate of 17% as a single agent, and tolerable toxicity in the
treatment of advanced gastric cancer. The aim of this study was to evaluate the
efficacy and toxicity of a combination of 5-fluorouracil (5-FU) and heptaplatin in
patients with advanced gastric cancer. Forty-seven chemotherapy-naive patients
with advanced or recurred gastric cancer were recruited. 5-FU was administered
over 120 hr by continuous intravenous infusion from day 1 to 5, at a daily dose of
1,000 mg/m 2 and heptaplatin was administered over 1 hr by intravenous infusion on day 1 at 400 mg/m 2
, and this cycle was repeated every 4 weeks. The response rate was 21%, median progression-free survival was 1.9 months (95% CI, 1.6 to 2.2 months). Median overall survival was 6.2 months (95% CI, 4 to 8.4 months) and the 1-yr survival rate was 29% for all patients. The most frequent toxicity was proteinuria. Toxicities were generally mild and reversible. This study demonstrates
that the combination of 5-FU/heptaplatin combination is less active but tolerated in
patients with advance gastric cancer. KCI Citation Count: 9